Skip to search formSkip to main contentSkip to account menu

Lactobacillus reuteri 100000000 UNT Chewable Tablet

Known as: Lactobacillus reuteri 100 Million Cells Chewable Tablet, Lactobacillus reuteri 100 Million UNT Chewable Tablet, Lactobacillus reuteri 100,000,000 UNT Chewable Tablet 
National Institutes of Health

Related topics

Related topics

3 relations
Chewable Tablet

Narrower (2)

Lactobacillus reuteri 100000000 UNT Chewable Tablet [BioGaia]Lactobacillus reuteri 100000000 UNT Chewable Tablet [Pedia-Lax Probiotic]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Twice‐a‐day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies
Bismuth is no longer available in Europe except as part of combination therapy. Lactobacillus reuteri has also been used as an… 
2018
2018
Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients.
Some patients with oral lichen planus (OLP) experience recurrent oral candidiasis(OC). Probiotic bacteria have shown to reduce… 
2015
2015
Nomenclature and syntaxonomic notes on some high-rank syntaxa of the European grassland vegetation
We present descriptions of a new order ( Ranunculo cortusifolii-Geranietalia reuteri and of a new alliance ( Stachyo lusitanicae… 
Review
2014
Review
2014
Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children.
Lactobacillus reuteri ATCC 55730 has been shown to provide a moderate clinical effect in the treatment of acute gastroenteritis… 
Highly Cited
2012
Highly Cited
2012
© 2012 Landes Bioscience. Do not distribute. Antifungal activity of Lactobacillus against Microsporum canis, Microsporum gypseum and Epidermophyton floccosum
Keywords: antifungal, lactic acid bacteria, Microsporum canis, Microsporum gypseum, Epidermophyton floccosumAbbreviations:WHO… 
2012
2012
Lactobacillus reuteri ATCC 55730 and L22 display probiotic potential in vitro and protect against Salmonella-induced pullorum disease in a chick model of infection.
2012
2012
Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease
We read with interest the informative and required investigation of bile-acid dysmetabolism, dysbiosis and inflammation in… 
Highly Cited
2011
Highly Cited
2011
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently… 
Highly Cited
2009
Highly Cited
2009
Oral colonization by Lactobacillus reuteri ATCC 55730 after exposure to probiotics.
OBJECTIVE The aim of this study was to investigate whether Lactobacillus reuteri ATCC 55730 can be detected in the oral cavity… 
1992
1992
Transformation ofLactobacillus reuteri with electroporation: Studies on the erythromycin resistance plasmid pLUL631
A high-frequency transformation system was developed forLactobacillus reuteri with the electroporation technique. With this… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)